Biotechnology and Pharmaceuticals · eu
Microbiome Therapy Moves Toward Solid Tumor Trials: MaaT034 Receives Early Development Feedback from FDA
MaaT034 aims to improve responses to cancer immunotherapy through gut microbial functions. FDA feedback on its manufacturing and nonclinical development strategy provides clearer direction for preparations for human trials; however, the trial has not yet been authorized, and the proposed launch in late 2027 remains dependent on funding.
Harnessing gut microbes to support cancer immunotherapy first requires meeting manufacturing and safety assessment requirements. French biotechnology company MaaT Pharma said on October 19 that its solid tumor therapy candidate MaaT034 had received early development feedback from the US Food and Drug Administration (FDA), supporting continued preparations for human trials. This development clarifies some submission requirements, but does not constitute trial authorization or provide evidence of efficacy in humans.
The pre-investigational new drug application consultation (pre-IND) focused on chemistry, manufacturing and controls (CMC) and nonclinical development, with potential indications including non-small cell lung cancer, melanoma and renal cell carcinoma. According to the company, the FDA considered its science- and risk-based strategy to appear appropriate; this assessment remains subject to review of the complete IND submission, and the company is still awaiting receipt and confirmation of the final meeting minutes.
One specific piece of feedback was that the FDA did not request additional nonclinical studies to support the safety of MaaT034 administration. However, the regulator requested that supplementary information from completed studies be included in the application. A Boursier.com report published by Fortuneo also relayed this requirement: work at this stage still includes completing the supporting information, and “no additional studies required” cannot be interpreted as comprehensive confirmation of safety.
MaaT034 remains at the preclinical stage. It is a microbial ecosystem selected by function and co-cultured, using what the company describes as a platform that does not depend on a continuous supply from donors. It is being developed for use alongside immune checkpoint inhibitors, with the aim of modulating immune responses through microbial functions and metabolites. The preclinical data cited by the company suggest potential for gut barrier repair and T-cell activation, among other effects; these findings do not yet establish that patients’ treatment responses or survival will improve as a result.
The clinical program also remains subject to discussion. MaaT Pharma plans to hold a separate Type C meeting with the FDA to discuss its clinical development plan and first-in-human trial design. The announcement did not disclose participant numbers, dosing schedules or primary endpoints, so it is not yet possible to assess how the first trial will evaluate the safety and biological activity of this microbiome therapy.
The company has proposed a possible launch in late 2027, contingent on obtaining the necessary regulatory clearances and sufficient funding. Both the company announcement and the Boursier.com report stated that the company estimates its cash will support operations through December 2026 and that it is seeking investment and strategic partnerships. Moving from submission preparations to treating the first participant will require both a clinical design and the financial resources to bridge that period.